16,167 trials (keyword fallback)
Head and Neck Neoplasms · Pheochromocytoma · Colorectal Neoplasms
Primary: Response Rate — 0; 0; 26; 11 Participants
Carcinoma, Non-Small-Cell Lung · Carcinoma, Small Cell Lung · Carcinoma, Thymic
Primary: Percentage of Enrolled Participants Testing Positive for Genomic Abnormality — 28.5; 44.2; 0; 24.9 percentage of participants
Non-small Cell Lung Cancer
Primary: Part 1: Overall Survival (OS) — 15.9; 20.1; 13.9 months — p=0.1782
Lung Cancer
Primary: Overall Survival — 14.4; 15.9; 16.4 months — p=0.12
Non Small Cell Lung Cancer
Primary: 3-Year Overall Survival Rate — 45 percentage of participants
Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer
Primary: Overall Survival (OS) in the TC3 or IC3-WT Populations — 13.1; 20.2 Months — p=0.0106
Non-small Cell Lung Cancer · Lung Cancer
Primary: Progression-Free Survival (PFS) in the Overall Population — 17.3; 14 Weeks
Acute Respiratory Distress Syndrome · Acute Lung Injury
Primary: Oxygenation — 10 Participants
Extensive Stage Small Cell Lung Carcinoma · Large Cell Lung Carcinoma · Neuroendocrine Carcinoma
Primary: Recommended Phase II Dose (Phase I) — 100 mg
Advanced Lung Non-Squamous Non-Small Cell Carcinoma · Recurrent Lung Non-Squamous Non-Small Cell Carcinoma · Stage IV Lung Cancer AJCC v8
Primary: Objective Response Rate (ORR) — 2 percentage of participants
Cystic Fibrosis
Primary: Feasibility of Participants Completing 2-week Study Visit — 25; 25; 0 Participants
Non-Small Cell Lung Cancer
Primary: Duration of Treatment of Anti-cancer Drugs — 11; 14; 9.4; 15.8 Months
Lung Cancer · Untreated Stage IV or Recurrent Squamous Cell Lung Cancers
Primary: Overall Response Rate — 18; 1; 5; 12 Participants
Non-small Cell Lung Cancer
Primary: Number of Participants Who Experienced Serious Adverse Events (SAE), Adverse Events (AE) Leading to Discontinuation, or Death — 4; 10; 8; 3 Participants
Multiple Sclerosis
Primary: Number of Patients With a Return of Disease Activity After the Third Month Post-first-infusion — 3; 6 Participants